LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis [version 1; peer review: 2 approved]

MLA

Ahmed Musa, et al. “LEISH2b - A Phase 2b Study to Assess the Safety, Efficacy, and Immunogenicity of the Leishmania Vaccine ChAd63-KH in Post-Kala Azar Dermal Leishmaniasis [Version 1; Peer Review: 2 Approved].” Wellcome Open Research, vol. 7, Aug. 2022. EBSCOhost, https://doi.org/10.12688/wellcomeopenres.17951.1.

APA

Ahmed Musa, Charles Lacey, Brima Younis, El Tahir Khalil, Rebecca Wiggins, Mohamed Osman, Paul Kaye, & Ada Keding. (2022). LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis [version 1; peer review: 2 approved]. Wellcome Open Research, 7. https://doi.org/10.12688/wellcomeopenres.17951.1

Chicago

Ahmed Musa, Charles Lacey, Brima Younis, El Tahir Khalil, Rebecca Wiggins, Mohamed Osman, Paul Kaye, and Ada Keding. 2022. “LEISH2b - A Phase 2b Study to Assess the Safety, Efficacy, and Immunogenicity of the Leishmania Vaccine ChAd63-KH in Post-Kala Azar Dermal Leishmaniasis [Version 1; Peer Review: 2 Approved].” Wellcome Open Research 7 (August). doi:10.12688/wellcomeopenres.17951.1.